⁶⁸Ga-DOTA-Tyr³-Octreotide PET for Assessing Response to Somatostatin-Receptor–Mediated Radionuclide Therapy

10.1080/02841860701441848

10.1200/JCO.2005.08.066

10.1200/JCO.2004.10.016

10.1023/A:1012272314550

10.1002/cncr.11105

10.1002/(SICI)1097-0142(19991015)86:8<1621::AID-CNCR33>3.0.CO;2-M

10.1200/JCO.2003.12.142

10.2967/jnumed.106.035667

Gabriel M, Andergassen U, Putzer D, et al. Innsbruck experience with targeted radionuclide therapy using different radiolabeled somatostatin analogs [abstract]. Eur J Nucl Med Mol Imaging . 2007;34(suppl 2):S220.

10.1093/jnci/92.3.205

Oberg K, Jelic S; ESMO Guidelines Working Group. Neuroendocrine gastroenteropancreatic tumors: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol . 2008;19(suppl 2):ii104–ii105.

10.1007/s00259-005-0006-1

10.1097/MNM.0b013e3282f1753d

2005, J Nucl Med., 46, 76S

10.1016/j.surg.2006.07.030

2006, Anticancer Res., 26, 703

2004, Eur J Nucl Med Mol Imaging., 31, 1038

2005, J Nucl Med., 46, 1310

2002, J Nucl Med., 43, 610

10.1007/s00259-005-1875-z

10.1259/bjr/34082277

10.1097/00006231-200208000-00005

10.1002/cncr.23469

1999, J Nucl Med., 40, 1602

10.1007/s00259-006-0110-x